PDF(Pubmed)
Abstract：
BACKGROUND: In Poland, active HCV infection affects between 0.4 and 0.5% of the population, i.e., about 150,000 people, while the number of patients with epilepsy is estimated to be 350,000-400,000. Currently available antiviral therapies show little interaction with neurological drugs. The aim of our study was to evaluate the effectiveness and safety of the treatment of chronic HCV infection in patients with coexisting epilepsy.
METHODS: A total of 184 epilepsy patients were selected from the group of 10,152 HCV-infected patients treated for HCV infection within the Epiter-2 database from 2015 to 2018. Comparing the effectiveness and safety of anti-HCV regimens between the patients with comorbid epilepsy and 3573 patients without comorbidities was our study\'s objective.
RESULTS: The effectiveness of anti-HCV treatment was high in both the sample and the control group. No statistically significant SVR difference was observed between the sample group, with ITT = 93.5% and mITT = 95.5%, and the control group, with ITT = 95.2% and mITT = 97.5%, regardless of the genotype and the stage of liver disease at the start of therapy. The treatment was safe in patients with epilepsy.
CONCLUSIONS: The effectiveness and safety of HCV treatment in patients with epilepsy are comparable to those of patients with no significant comorbidities.
METHODS: A total of 184 epilepsy patients were selected from the group of 10,152 HCV-infected patients treated for HCV infection within the Epiter-2 database from 2015 to 2018. Comparing the effectiveness and safety of anti-HCV regimens between the patients with comorbid epilepsy and 3573 patients without comorbidities was our study\'s objective.
RESULTS: The effectiveness of anti-HCV treatment was high in both the sample and the control group. No statistically significant SVR difference was observed between the sample group, with ITT = 93.5% and mITT = 95.5%, and the control group, with ITT = 95.2% and mITT = 97.5%, regardless of the genotype and the stage of liver disease at the start of therapy. The treatment was safe in patients with epilepsy.
CONCLUSIONS: The effectiveness and safety of HCV treatment in patients with epilepsy are comparable to those of patients with no significant comorbidities.
摘要：
背景：在波兰，活跃的HCV感染影响了0.4％至0.5％的人口，即，大约15万人，而癫痫患者的数量估计为350,000-400,000。目前可用的抗病毒疗法显示与神经药物的相互作用很小。我们研究的目的是评估合并癫痫患者治疗慢性HCV感染的有效性和安全性。
方法：从2015年至2018年在Epiter-2数据库中接受HCV感染治疗的10,152名HCV感染患者中选择了184名癫痫患者。我们的研究目的是比较合并癫痫患者和3573例无合并症患者抗HCV方案的有效性和安全性。
结果：在样本组和对照组中，抗HCV治疗的有效性都很高。样本组间SVR差异无统计学意义,ITT=93.5%，MITT=95.5%，和对照组，ITT=95.2%，MITT=97.5%，无论治疗开始时的基因型和肝病阶段。癫痫患者的治疗是安全的。
结论：HCV治疗癫痫患者的有效性和安全性与无明显合并症的患者相当。
方法：从2015年至2018年在Epiter-2数据库中接受HCV感染治疗的10,152名HCV感染患者中选择了184名癫痫患者。我们的研究目的是比较合并癫痫患者和3573例无合并症患者抗HCV方案的有效性和安全性。
结果：在样本组和对照组中，抗HCV治疗的有效性都很高。样本组间SVR差异无统计学意义,ITT=93.5%，MITT=95.5%，和对照组，ITT=95.2%，MITT=97.5%，无论治疗开始时的基因型和肝病阶段。癫痫患者的治疗是安全的。
结论：HCV治疗癫痫患者的有效性和安全性与无明显合并症的患者相当。
